OpenURL Connection Search

Select item for more details and to access through your institution.

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies.
Published in:
EMBO Molecular Medicine, 2020, v. 12, n. 2, p. N.PAG, doi. 10.15252/emmm.201911223
By:
- Huyghe, Leander;
- Van Parys, Alexander;
- Cauwels, Anje;
- Van Lint, Sandra;
- De Munter, Stijn;
- Bultinck, Jennyfer;
- Zabeau, Lennart;
- Hostens, Jeroen;
- Goethals, An;
- Vanderroost, Nele;
- Verhee, Annick;
- Uzé, Gilles;
- Kley, Niko;
- Peelman, Frank;
- Vandekerckhove, Bart;
- Brouckaert, Peter;
- Tavernier, Jan
Publication type:
Article
Nuclear import of the DSCAM‐cytoplasmic domain drives signaling capable of inhibiting synapse formation.
Published in:
EMBO Journal, 2019, v. 38, n. 6, p. N.PAG, doi. 10.15252/embj.201899669
By:
- Sachse, Sonja M;
- Lievens, Sam;
- Ribeiro, Luís F;
- Dascenco, Dan;
- Masschaele, Delphine;
- Horré, Katrien;
- Misbaer, Anke;
- Vanderroost, Nele;
- De Smet, Anne Sophie;
- Salta, Evgenia;
- Erfurth, Maria‐Luise;
- Kise, Yoshiaki;
- Nebel, Siegfried;
- Van Delm, Wouter;
- Plaisance, Stéphane;
- Tavernier, Jan;
- De Strooper, Bart;
- De Wit, Joris;
- Schmucker, Dietmar
Publication type:
Article
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state.
Published in:
Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01908-6
By:
- Van Lint, Sandra;
- Van Parys, Alexander;
- Van Den Eeckhout, Bram;
- Vandamme, Niels;
- Plaisance, Stephane;
- Verhee, Annick;
- Catteeuw, Dominiek;
- Rogge, Elke;
- De Geest, Jennifer;
- Vanderroost, Nele;
- Roels, Jana;
- Saeys, Yvan;
- Uzé, Gilles;
- Kley, Niko;
- Cauwels, Anje;
- Tavernier, Jan
Publication type:
Article

Found: 3

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies.

Nuclear import of the DSCAM‐cytoplasmic domain drives signaling capable of inhibiting synapse formation.

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state.